Telomere maintenance patterns as prognostic clues in high-risk neuroblastoma
Official title: Telomere Maintenance Mechanisms as Prognostic Indicators for Neuroblastoma
Funded at Texas Tech University Health Scis Center · NIH-11228627 · Data updated 2026-11-12
This grant studies how the way cancer cells keep their chromosomes intact may predict outcomes for children with high-risk neuroblastoma and guide future treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Texas Tech University Health Scis Center NIH-funded |
| Lab location | 1 site (Lubbock, United States) |
| Project start | August 29, 2018 |
| Project end | August 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $1,105,938 |
| NIH project number | 2R01CA217251-06A1 |
| Project ID | NIH-11228627 on NIH RePORTER |
Who could benefit from this research
✓Could help
Children with high-risk neuroblastoma whose tumors can be classified by telomere maintenance mechanisms.
✕Less likely to help
Patients whose tumors do not fit the studied telomere mechanisms or whose disease biology is not driven by these pathways may see limited benefit.
What this research studies
Children with high-risk neuroblastoma have varied outcomes, and this project looks at the cellular math behind their cancer's survival. By measuring telomere maintenance mechanisms, including telomerase activity and ALT markers, researchers aim to categorize tumors into groups with distinct clinical trajectories. The work builds on prior findings and uses tumor samples from national trials to refine prognosis and potentially tailor therapies. The ultimate goal is to translate these molecular insights into more accurate predictions and better, targeted care for patients.
Why it matters
Potential benefit: If successful, patients could receive more precise prognostic information and therapies tailored to their tumor's telomere maintenance profile.
How similar studies have gone: Previous work has shown that telomere maintenance markers can define groups with different outcomes in high-risk neuroblastoma, guiding future research.
Where this research is happening
-
Texas Tech University Health Scis Center
Lubbock, United States Active
Researchers
- Principal investigator: Reynolds, Charles Patrick — Texas Tech University Health Scis Center
- Study coordinator: Reynolds, Charles Patrick
Related research
Other NIH-funded projects on the same topics.
-
Computational and functional screens to find actionable neuroblastoma drivers
Researchers are using advanced computer analysis and lab tests to find new genes and drug targets in neuroblastoma, aiming to improve outcomes for children.
-
Understanding ATRX in neuroblastoma: new protein functions and treatment clues
A short, patient-friendly look at a study exploring how altered ATRX proteins in neuroblastoma might influence disease behavior and response to therapy.
-
Neuroblastoma and radiopharmaceuticals: understanding how targeted radiation affects kids’ tumors
A pediatric cancer grant studies how a targeted radiotherapy called 131I-MIBG affects tumor and surrounding cells in children with high-risk neuroblastoma.
-
Bispecific antibodies to help kids fight neuroblastoma and brain tumors
A pediatric-focused grant tests new bispecific antibodies that help the immune system attack childhood cancers like neuroblastoma and brain tumors.
-
ADEPT-STAR therapy for high risk neuroblastoma
A new cell-based therapy approach aims to help children with high-risk neuroblastoma by using off-the-shelf, donor-derived treatments.
-
MYCN and ferroptosis: a new vulnerability in pediatric neuroblastoma
A study in children with neuroblastoma looks at a new vulnerability called ferroptosis that could be exploited to more effectively treat tumors with the MYCN gene amplification.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.